Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
The importance of trust / Professor Philip D Walson, MD, USA
Response to the Opinion entitled ‘Biosimilars drug development: time for a paradigm shift?’ / Robin Thorpe, PhD, FRCPath, UK
Social trust and regional variation in the adoption of biosimilars in Italy and Germany / Professor James C Robinson, PhD, MPH
US prescribers’ attitudes and perceptions about biosimilars / Ralph D McKibbin, MD; Michael S Reilly, Esq
Pharmacokinetic bioequivalence of sitagliptin phosphate tablet formulations: a randomized, open-label, crossover study in healthy volunteers / Chuei Wuei Leong, PhD; Elton Sagim, BBiomedSc; Kar Ming Yee, BPharm; Muhammad Shalhadi Saharuddin, BSc; Nik Mohd Zulhakimi Nik Abdullah, BSc; Noramirah Farhanah Saberi, BSc; Rajavikraman Boopathy, DipSc; Shahnun Ahmad, MBBS; Atiqah Amran, BSc; Raman Batheja, PhD; Rajan Sharma, MBBS; Kiran Kumar Vuppalavanchu, MPharm, Malaysia
Pharmacokinetics and relative bioavailability of sitagliptin hydrochloride and sitagliptin phosphate tablets formulations: a randomized, open-label, crossover study in healthy male volunteers / Chuei Wuei Leong, PhD; Elton Sagim, BBiomedSc, Kar Ming Yee, BPharm; Muhammad Shalhadi Saharuddin, BSc; Sharifah Radziah Syed Abd Rahim, MSc; Khairil Sabri, BSc; Mohd Zulhairi Jamaluddin, BSc; Shahnun Ahmad, MBBS; Atiqah Amran1, BSc; Rabab F Tayyem, PhD, Malaysia
Development of Ph. Eur. standards for therapeutic monoclonal antibodies: infliximab case study / Mihaela Buda, PhD
Biosimilars drug development: time for a paradigm shift? / Sandeep N Athalye, MS; Shivani Mittra, MPharm, PhD; Ankitkumar M Ranpura, MD
Key factors for successful uptake of biosimilars: Europe and the US / Michael S Reilly, Esq; Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP, USA
Non-medical switching of biologicals/biosimilars Canada, Europe and the US: a webinar report / Michael S Reilly, Esq; Gail Attara; Ralph D McKibbin, MD, FACP, FACG, AGAF; Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP, USA / Canada
Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD, Iran
Biosimilars approved in Brazil 2022 / Sílvia Helena Cestari de Oliveira, MSc, Brazil
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.